The Role of Sex and HCV Co-Infection in HIV Therapy

描述（由申请人提供）：本申请提出了对科罗拉多大学艾滋病研究中心（UC-CFAR）的补充，以解决艾滋病研究的两个重要和未充分研究的领域： * 性别和年龄在艾滋病毒治疗中的作用， * B型肝炎病毒（HBV）和丙型肝炎病毒（HCV）共感染在HIV发病机制和治疗研究中的意义 该申请的具体目标是：（1）通过将抗逆转录病毒临床药理学资源和专业知识与UC-CFAR临床，实验室和开发核心的活动相结合，建立合作研究能力;和（2）通过前瞻性评价抗逆转录病毒药物在HIV感染女孩、妇女、以及HBV或HCV合并感染的患者。本提案中的研究人员已在上述艾滋病研究领域建立了专门知识， 在与其他学科的调查人员建立合作方面有良好的记录。在本补充中提出的工作提供了一个机会，整合资源和专业知识在抗逆转录病毒临床药理学，这补充了现有的研究正在进行的UC-CFAR，并建立新的合作研究计划，目前不存在于UC-CFAR与明确的潜力，以保持该计划通过更传统的资金来源完成补充后。资助这一补充将促进新知识的发现和应用，这些新知识可以直接转化为艾滋病毒感染者的管理，以增加艾滋病毒和HCV/HBV治疗成功的可能性，并最大限度地减少不良反应的风险。

DESCRIPTION (provided by applicant): This application proposes a supplement to the University of Colorado Center for AIDS Research (UC-CFAR) to address two important and under-studied areas of AIDS research: * The role of sex and gender, and age in HIV treatment, and * The implications of co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV pathogenesis and therapeutic studies The specific aims of this application are: (1) To build collaborative research capacity by integrating antiretroviral clinical pharmacology resources and expertise with the activities of the UC-CFAR clinical, laboratory, and developmental cores; and (2) To initiate program development and generate preliminary data by prospectively evaluating clinical pharmacologic characteristics of antiretrovirals in a longitudinal cohort of HIV-infected girls, women, and patients with HBV or HCV co-infection. The investigators in this proposal have established expertise in the AIDS research areas listed above, and have a demonstrated track record for establishing collaborations with investigators in other disciplines. The work proposed in this supplement provides an opportunity to integrate resources and expertise in antiretroviral clinical pharmacology, which complements existing research being undertaken by the UC-CFAR, and to build new collaborative research programs that presently do not exist at the UC-CFAR with the clear potential to maintain the program through more traditional sources of funding after completion of the supplement. Funding of this supplement would facilitate the discovery and application of new knowledge that can be directly translated into the management of the HIV infected individual to increase the likelihood of therapeutic success with HIV and HCV/HBV treatments and minimize the risk of adverse effects.